Health · 5 September 2026

Surrey NHS trust joins trial of new Alzheimer's prevention drug

Surrey NHS trust is the first in Europe to take part in the global trial for a new drug called Trontinemab. Researchers hope Trontinemab can delay or even stop Alzheimer's, which causes up to 80% of dementia cases. The drug targets a sticky protein that accumulates between brain cells, and 1,600 healthy adults between 55 and 80 years old are being recruited internationally.

By BriefTea Editorial · 5 September 2026 at 8:15

Reported by BBC · How we write briefs

Get the app

Understand this story

What is Alzheimer's? How do new drugs get approved? Why is prevention so important?

More briefs

TechnologyCoroner Says TikTok Content May Have Played Part in Norfolk Girl's Death HealthAI Can Predict Cancer Survival From a Single Face Photo, Study Finds HealthCovid Inquiry Finds Care Homes Were an 'Afterthought' in Pandemic HealthNHS Trust Prosecuted Over Two Girls' Sepsis Deaths HealthPublic Support for NHS Founding Principles Is Falling HealthThe Times article about antidepressants and intimacy failed to load More health stories → Browse all stories →